10.1016/j.ijbiomac.2024.132256 [DOI] [PubMed] [Google Scholar] Yabe D., Kawamori D., Seino Y., Oura T., Takeuchi M
Can I stop after I reach my weight loss goal
Bioavailability of oral hydroxocobalamin
Implications for clinical practice: If you manage T2D patients, now is the time to ask: Have I considered liver health in this patient? Have I screened for advanced fibrosis? Is my choice of glucose-lowering therapy optimised for both glycaemic and hepatic benefit? Even in settings where hepatology referrals are limited, simple non-invasive tests (e.g., FIB-4) may help stratify risk
My initial hypothesis was slightly different, shares Dr
employee for Merck Research Laboratories (spouse) 2017-2020 and Janssen (spouse) May 2020 present